<DOC>
	<DOCNO>NCT01838850</DOCNO>
	<brief_summary>CS-8635 combine three widely prescribe antihypertensive medication , olmesartan medoxomil ( OM ) , amlodipine ( AML ) , hydrochlorothiazide ( HCTZ ) , low blood pressure . The purpose study evaluate efficacy safety triple therapy CS-8635 compare dual therapy Korean patient hypertension control dual fix dose combination therapy ( Olmetec® Plus ) . The treatment use study follow : Run-in period -OM/HCTZ 20/12.5 mg ( Olmetec® Plus 20/12.5 mg ) ; Double blind treatment period - OM/AML/HCTZ 20/5/12.5mg ( CS8635 20/5/12.5mg ) + match placebo vs.OM/HCTZ 20/12.5mg ( Olmetec® Plus 20/12.5 mg ) + match placebo ; Open label extension period - OM/AML/HCTZ 40/5/12.5mg ( CS8635 40/5/12.5mg ) OM/AML/HCTZ 20/5/12.5mg ( CS8635 20/5/12.5mg ) .</brief_summary>
	<brief_title>Efficacy Safety Study Olmesartan Medoxomil , Amlodipine Hydrochlorothiazide Combination Therapy Patients With Hypertension Not Controlled With Olmesartan Medoxomil Hydrochlorothiazide Combination Therapy</brief_title>
	<detailed_description>Please refer arm , outcome measure eligibility criterion detail .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion Criteria Screening Male female age 20 75 year Voluntary write informed consent participation study Patients hypertension either newly diagnose without treatment antihypertensive drug within 4 week screen , mean seat diastolic blood pressure ( msDBP ) ≥ 100 mmHg screening , Patients stable dose antihypertensive drug least 4 week runin period meet follow blood pressure criterion screen : Monotherapy : msDBP ≥ 95 mmHg , Dual combination therapy : msDBP ≥ 90 mmHg , Triple combination therapy : 70 mmHg ≤ msDBP &lt; 90 mmHg Inclusion criterion randomization msSBP/DBP randomization : msSBP ≥ 140 mmHg ( msSBP ≥ 130 mmHg subject diabetes chronic renal disease ) , msDBP ≥ 90 mmHg ( msDBP ≥ 80 mmHg subject diabetes chronic renal disease ) msDBP ≥ 115mmHg msSBP ≥ 200 mmHg measure screening randomization Patients minimax blood pressure difference SeSBP ≥ 20 mmHg SeDBP ≥ 10 mmHg choose arm screening Patients blood pressure difference SeSBP ≥ 20 mmHg SeDBP ≥ 10 mmHg arm screen Patients hypersensitivity investigational product component Patients medical history hypersensitivity sulfonamide , dihydropyridine , thiazide diuretic History secondary hypertension history disease suspect secondary hypertension Symptomatic orthostatic hypotension Uncontrolled diabetes mellitus Severe heart disease , ischemic heart disease , peripheral vascular disease Clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter , arrhythmia consider clinically significant Hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically significant stenosis aortic valve mitral valve . Severe cerebrovascular disorder Known moderate malignant retinopathy Consumption disease , autoimmune disease , connective tissue disease Patients require chronic antiinflammatory treatment Anuria severe renal failure Severe hepatic failure , AST ALT &gt; 3 time upper limit normal , biliary obstruction , biliary cirrhosis , cholestasis Patients treat hyponatremia , hypokalemia , hyperkalemia , hypercalcemia , symptomatic hyperuricemia Addison 's disease Glucosegalactose malabsorption , galactose intolerance , Lapp lactase deficiency Gastrointestinal tract disease surgical operation may affect absorption , distribution , metabolism , excretion drug , presence active gastritis gastrointestinal/rectal bleeding consider clinical significant investigator , active inflammatory bowel syndrome within last 12 month , etc Patients history suspect drug alcohol abuse Pregnant lactate woman , woman childbearing potential agree use appropriate contraceptive method progestin hormone therapy ( Oral , implant ) , intrauterine device , barrier method contraception ( condom occlusive cap ( diaphragm cervical/vault cap ) spermicide ) , male sterilisation true abstinence Patients participate clinical study within 1 month prior screen Patients consider incapable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>